Edgen Stock·Sep 22 2025, 14:48戻る
戻る
Pfizer Navigates Patent Expirations and Legal Challenges Amidst Pipeline Progress and Valuation Debates
Edgen Stock·Sep 22 2025, 14:48
[1] A Look at Pfizer’s (PFE) Valuation Following Fresh Legal Rulings and Positive COVID Vaccine Trial Data[2] Should Pfizer's (PFE) Antitrust Settlement and R&D Push Shift Investor Focus on Long-Term Risks? - Simply Wall St[3] Phase 3 Data Supports FDA Approval for Pfizer Inc. (PFE)'s 2025-2026 COVID-19 Vaccine